Skip to content

Study · Not a test of the peptide alone · 2026

5 results

Real-world prescribing patterns and early weight and blood pressure outcomes of GLP-1-based therapies: a retrospective observational study in the United Arab Emirates.

Almemari S, Almulla N, Alsarraf Y, Badri G, Khan NS

BMC endocrine disorders12 Apr 2026Cited by 2 (Europe PMC)

PMID41968307 (opens in a new tab)PMCIDPMC13181871 (opens in a new tab)DOI10.1186/s12902-026-02273-3 (opens in a new tab)PepBankPUB-41968307
Read at sourcePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study5

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone5

In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Tirzepatide.

  1. 01HumanNot a test of Tirzepatide aloneObservational studyEfficacy outcome

    After adjustment, treatment group (GLP-1 receptor agonist or tirzepatide) was not independently associated with achieving weight loss of 5% or more.

    In plain wordsAfter adjustment, the choice between a GLP-1 drug and tirzepatide was not linked to losing at least 5% of weight.

    Peptide
    Tirzepatide
    Outcome
    No significant changeAssociation of treatment group with weight loss of 5% or more
    Study

    n: not reported in source

    Comparator
    GLP-1 RA versus tirzepatide
    Analysis
    Exploratory
    Outcome group
    Body weight · Metabolic and weight

    Source sentences

    Summary
    After adjustment for age group, sex, BMI category, treatment group, and HbA1c category, no independent association was observed between treatment group and achieving ≥ 5% weight loss.
    2 context sentences
    Summary · context
    An exploratory multivariable logistic regression adjusted for age group, sex, BMI category, treatment group, and HbA1c category was performed to evaluate factors associated with achieving clinically meaningful weight loss (≥ 5%).
    Summary · context
    This retrospective observational study included adult patients prescribed GLP-1 RA or tirzepatide (dual GIP/GLP-1 RA) between January 2022 and December 2024.

    In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.

  2. 02HumanNot a test of Tirzepatide aloneObservational studyOther

    In a UAE tertiary care setting, use of GLP-1-based therapies (GLP-1 receptor agonists and tirzepatide) rose by 371.7% over the study period, with a shift toward tirzepatide.

    In plain wordsIn a UAE hospital setting, use of GLP-1-based drugs, including tirzepatide, rose by 371.7% over the study period.

    Peptide
    Tirzepatide
    Outcome
    IncreaseUtilization of GLP-1-based therapies
    Study

    n = 1,744

    Outcome group
    Patterns of use · Metabolic and weight

    Measurements

    utilization increase
    371.7%
    GLP-1-based therapies

    Source sentences

    Summary
    Utilization of GLP-1–based therapies increased by 371.7% over the study period, with a marked shift toward tirzepatide as the predominant agent.
    1 context sentence
    Summary · context
    This retrospective observational study included adult patients prescribed GLP-1 RA or tirzepatide (dual GIP/GLP-1 RA) between January 2022 and December 2024.

    In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.

  3. 03HumanNot a test of Tirzepatide aloneObservational studyEfficacy outcome

    In adults receiving GLP-1 receptor agonists or tirzepatide (pooled), mean weight fell by 3.91% in patients with paired follow-up data.

    In plain wordsIn adults on GLP-1 drugs or tirzepatide, taken together, average weight fell by 3.91% in those with follow-up data.

    Peptide
    Tirzepatide
    Outcome
    DecreaseMean percentage weight reduction
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight

    Measurements

    mean percentage weight reduction
    3.91%
    GLP-1 RA and tirzepatide pooled

    Source sentences

    Summary
    the mean percentage weight reduction was 3.91% (SD 7.32; 95% CI 2.70 to 5.12)
    2 context sentences
    Summary · context
    The mean treatment duration among patients with follow-up data was 6.99 months.
    Summary · context
    This retrospective observational study included adult patients prescribed GLP-1 RA or tirzepatide (dual GIP/GLP-1 RA) between January 2022 and December 2024.

    In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.

  4. 04HumanNot a test of Tirzepatide aloneObservational studyEfficacy outcome

    In adults receiving GLP-1 receptor agonists or tirzepatide (pooled), 35.6% achieved weight loss of 5% or more.

    In plain wordsIn adults on GLP-1 drugs or tirzepatide, taken together, 35.6% lost at least 5% of their weight.

    Peptide
    Tirzepatide
    Outcome
    Not applicableWeight loss of 5% or more
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight

    Measurements

    proportion with weight loss 5% or more
    35.6%
    GLP-1 RA and tirzepatide pooled

    Source sentences

    Summary
    35.6% achieving ≥ 5% weight loss
    1 context sentence
    Summary · context
    This retrospective observational study included adult patients prescribed GLP-1 RA or tirzepatide (dual GIP/GLP-1 RA) between January 2022 and December 2024.

    In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.

  5. 05HumanNot a test of Tirzepatide aloneObservational studyEfficacy outcome

    In adults receiving GLP-1 receptor agonists or tirzepatide (pooled), 25.1% experienced weight gain.

    In plain wordsIn adults on GLP-1 drugs or tirzepatide, taken together, 25.1% gained weight.

    Peptide
    Tirzepatide
    Outcome
    Not applicableWeight gain
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight

    Measurements

    proportion with weight gain
    25.1%
    GLP-1 RA and tirzepatide pooled

    Source sentences

    Summary
    25.1% experiencing weight gain.
    1 context sentence
    Summary · context
    This retrospective observational study included adult patients prescribed GLP-1 RA or tirzepatide (dual GIP/GLP-1 RA) between January 2022 and December 2024.

    In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:07 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.